PubMed

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L; LEAD-4 Study Investigators.

Diabetes Care. 2009 Jul;32(7):1224-30. Epub 2009 Mar 16.PMID: 19289857 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group.

Diabetes Care. 2004 Jun;27(6):1335-42.PMID: 15161785 [PubMed - indexed for MEDLINE]Related articlesFree article

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.

Seino Y, Rasmussen MF, Zdravkovic M, Kaku K.

Diabetes Res Clin Pract. 2008 Aug;81(2):161-8. Epub 2008 May 20.PMID: 18495285 [PubMed - indexed for MEDLINE]Related articles

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Roberts VL, Stewart J, Issa M, Lake B, Melis R.

Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW.

Clin Ther. 2005 Oct;27(10):1548-61.PMID: 16330291 [PubMed - indexed for MEDLINE]Related articles

Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.

Nauck M, Marre M.

Postgrad Med. 2009 May;121(3):5-15.PMID: 19491535 [PubMed - indexed for MEDLINE]Related articlesFree article

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group.

Lancet. 2009 Jul 4;374(9683):39-47. Epub 2009 Jun 8.PMID: 19515413 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group.

Diabetes Care. 2006 Dec;29(12):2638-43.PMID: 17130197 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG.

Ann Intern Med. 2007 Apr 3;146(7):477-85. Erratum in: Ann Intern Med. 2007 Jun 19;146(12):896. PMID: 17404349 [PubMed - indexed for MEDLINE]Related articlesFree article

Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.

Diabetes Obes Metab. 2006 Nov;8(6):650-60.PMID: 17026489 [PubMed - indexed for MEDLINE]Related articles

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

Fonseca V, Rosenstock J, Patwardhan R, Salzman A.

JAMA. 2000 Apr 5;283(13):1695-702. Erratum in: JAMA 2000 Sep 20;284(11):1384. PMID: 10755495 [PubMed - indexed for MEDLINE]Related articlesFree article

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group.

Diabet Med. 2009 Mar;26(3):268-78.PMID: 19317822 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group.

Diabetes Care. 2009 Jan;32(1):84-90. Epub 2008 Oct 17.PMID: 18931095 [PubMed - in process]Related articlesFree article

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.

DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS; Saxagliptin 014 Study Group.

Diabetes Care. 2009 Sep;32(9):1649-55. Epub 2009 May 28.PMID: 19478198 [PubMed - indexed for MEDLINE]Related articles

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.

Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group.

Diabet Med. 2005 Aug;22(8):1016-23.PMID: 16026367 [PubMed - indexed for MEDLINE]Related articles

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.PMID: 16291411 [PubMed - indexed for MEDLINE]Related articles

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.PMID: 18158078 [PubMed - indexed for MEDLINE]Related articles

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group.

Diabetes Care. 2007 Aug;30(8):1979-87. Epub 2007 May 7. Erratum in: Diabetes Care. 2008 Aug;31(8):1713. PMID: 17485570 [PubMed - indexed for MEDLINE]Related articlesFree article